t(2;13)(q35;q14) that forms fusion gene PAX3-FOXO1A; identified in 75% of fusion-positive ARMS cases. 1,2 t(1;13)(p36;q14) that forms fusion gene PAX7-FOXO1A; identified in 25% of fusion-positive ARMS cases. 3, 4 t(2;X)(q35;q13) that forms fusion gene PAX3-AFX1; identified in o1% of ARMS cases. 5 t(2;2)(q35;p23) that forms fusion gene PAX3-NCOA1; identified in o1% of ARMS cases. 6, 7 Tetraploidy is common in ARMS and occurs in 77% of ARMS demonstrated in one of the studies. 8 PAX7-FOXO1A fusions are commonly amplified. 9 Amplification of chromosome 2p24 region including MYCN gene occurs in 13% of cases of fusion-positive ARMS but has no significant association with clinical outcome. 10 Amplification of chromosome 12q13-14 region including CDK4 gene occurs in 12% of cases of fusion-positive ARMS (majority are PAX3-FOXO1A fusion) and is associated with worse outcome. 10 TFAP2 b (6p24), CDH3 (16q22.1) and CNR1 (6q14-q15) are highly expressed in fusion-positive ARMS, irrespective of tumour histology. 11 Approximately 20-30% of ARMS have no PAX-FOXO1A fusion (ie, fusion negative ARMS). Oligonucleotide microarrays have demonstrated that fusion-negative ARMS has a distinctive gene expression profile different from fusion-positive ARMS. Some gene expression studies show that fusion-negative ARMS constitutes a heterogeneous group that overlaps with embryonal rhabdomyosarcoma (ERMS), with frequent whole-chromosome copy number changes, notably gain of chromosome 8 with associated high levels of expression of genes from this chromosome. [11] [12] [13] 1.6 Analytical methods Routine cytogenetic karyotyping on fresh, unfixed tissue. Reverse transcriptase (RT)-PCR on fresh, frozen or formalin-fixed, paraffin-embedded tissues. Fluorescence in situ hybridisation (FISH) on either cytologic touch preparations or formalin-fixed, paraffin-embedded tissue. Microarray for gene or protein expression analysis is currently only used in research field, but may be used as a clinical test in the future.
Analytical validation
Although the subclassification of rhabdomyosarcoma has traditionally relied on histological analysis, cytogenetic and molecular genetic analytic methods are increasingly being used as standard confirmatory tests. All testing should be validated based on histological criteria, but future treatment protocols may rely on fusion status rather than histology.
1.8 Estimated frequency of the disease (incidence at birth ('birth prevalence') or population prevalence) The incidence for overall rhabdomyosarcomas is 4.5 cases per million children/adolescents (age 0-19) per year in the United States between 1975 and 2005, of which ARMS account for 23%. 14 1.9 If applicable, prevalence in the ethnic group of investigated person In the United States between 1975 and 2005, African-American children had slightly higher rates of ARMS than Caucasian children (1.3 of 1 000 000 vs 1.0 of 1 000 000, respectively). 14 
Diagnostic setting
Comment: Patients with fusion-positive ARMS have a significantly worse outcome than those with fusion-negative lesions having similar histology. 15 Some studies suggest that tumours with PAX7 fusions have a better prognosis than other ARMS. 13, 16 2. TEST CHARACTERISTICS
Analytical sensitivity (proportion of positive tests if the genotype is present)
Routine cytogenetic karyotyping: 28% 17 RT-PCR: 25-86% 17, 18 FISH: 38-88%. 18, 19 Comment: Depends on the technique and methods used in each laboratory, the sensitivity may vary. False negative results with routine cytogenetic method may be associated with normal cellular components overgrowing tumour cells and low-level gene expression may cause false negative results associated with RT-PCR.
Analytical specificity (proportion of negative tests if the genotype is not present)
Routine cytogenetic karyotyping: 100% 17 RT-PCR: 93-100% 17, 18 FISH 100%. 18 Comment: Depends on the technique and methods used in each laboratory, the specificity may vary.
Clinical sensitivity (proportion of positive tests if the disease is present)
The clinical sensitivity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be made case by case. Approximately 70-80%. Around 70-80% ARMS (so called fusion-positive ARMS) possess either PAX3-FOXO1A or PAX7-FOXO1A translocations. Approximately 25% of cases have classic ARMS histology, but do not contain a fusion gene (so called fusion-negative ARMS). Gene expression arrays indicate that fusion-negative ARMS constitute a heterogeneous group that overlaps with ERMS. Although PAX3-FOXO1A tumours comprise a molecularly homogeneous entity with a uniformly poor prognosis, PAX7-FOXO1A-positive tumours exhibit gene amplification rather than overexpression. This subset may have a better prognosis than other alveolar genetic subtypes. 13 18 3. CLINICAL UTILITY 3.1 (Differential) diagnostics: The tested person is clinically affected (To be answered if in 1.10 'A' was marked) 3.1.1 Can a diagnosis be made other than through a genetic test?
Comment: The diagnosis of ARMS is currently based on routine histology, but some strongly feel that it should be supplanted by genetic studies. 11, 13, 16, 18, 20, 21 The current gold standard for the diagnosis of ARMS is the combination of classic or solid 'alveolar' histological features and strong reactivity to myogenin by immunohistochemistry. [21] [22] [23] [24] [25] New study has shown that fusion-positive ARMS may be detected by using a set of immunohistochemical markers, AP2b and P-cadherin, with a specificity of 98% and a sensitivity of 64%. 26 However, at present time, cytogenetic testing is still a key ancillary test when the tumours do not have classic ARMS histological features or strong expression of myogenin or myoD1.
Describe the burden of alternative diagnostic methods to the patient.
Rhabdomyosarcoma is the most common soft tissue tumour in paediatric population. It has been subclassified into two major categories: ERMS and ARMS. In general, ARMS carries an unfavourable prognosis with an aggressive clinical behaviour and a poor response to chemotherapy; thus low-stage disease requires aggressive The treatment is based on assessment of risk factors and tumour site. In general, ARMS patients belong to the intermediate-to high-risk groups (depending on stage, age and group) and are not treated as low-risk patients.
Studies have shown that patients with ARMS have greater 10-year FFS rates and overall survival rates, compared with patients who receive no radiation therapy, when they receive radiation therapy in addition to adjuvant multiagent chemotherapy and local resection. 29, 30 
